
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

DAVION HEALTHCARE PLC

(Name of Issuer)

ORDINARY SHARES of (euro)0.01 par value per share

(Title of Class of Securities)

(CUSIP Number)

**Jack Kaye C/o
Davion Healthcare Plc, Unit A, West Cork Business & Technology Park
Clonakilty, County Cork, L2, P85 FV48
353 238 808 958**

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

08/11/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.

1 Name of reporting person

JACK HARRY KAYE

2 Check the appropriate box if a member of a Group (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Citizenship or place of organization

Sole Voting Power

10,268,948.00

Shared Voting Power

0.00

Sole Dispositive Power

10,268,948.00

Shared Dispositive Power

0.00

Aggregate amount beneficially owned by each reporting person

10,268,948.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Percent of class represented by amount in Row (11)

41.08 %

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: This Amendment No. 1 to Schedule 13D (this "Amendment No. 1") amends and supplements the Schedule 13D originally filed with the Securities and Exchange Commission on April 17, 2026 (the "Schedule 13D") relating to the ordinary shares, nominal value (euro)0.01 per share (the "Ordinary Shares"), of Davion Healthcare plc, an Irish public limited company (the "Issuer"). Capitalized terms used but not otherwise defined herein have the meanings ascribed to such terms in the Schedule 13D. Except as specifically amended and supplemented by this Amendment No. 1, the Schedule 13D remains unchanged.

SCHEDULE 13D

CUSIP No.

Name of reporting person

RALLINSON CORP

Check the appropriate box if a member of a Group (See Instructions)

(b)

SEC use only

Source of funds (See Instructions)

00

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

	☐	Citizenship or place of organization
6		WYOMING
		Sole Voting Power
	7	0.00
Number of Shares Beneficially Owned by Each Reporting Person With:		Shared Voting Power
	8	0.00
		Sole Dispositive Power
	9	0.00
		Shared Dispositive Power
	10	0.00
		Aggregate amount beneficially owned by each reporting person
11		0.00
		Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
12		☐
		Percent of class represented by amount in Row (11)
13		0 %
		Type of Reporting Person (See Instructions)
14		CO

SCHEDULE 13D

CUSIP No.

		Name of reporting person
1		RALLINSON LTD
		Check the appropriate box if a member of a Group (See Instructions)
2		☐ (a)
		☐ (b)
3		SEC use only
		Source of funds (See Instructions)
4		OO
		Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
5		☐
		Citizenship or place of organization
6		CYPRUS
Number of Shares Beneficially Owned by Each Reporting Person With:		Sole Voting Power
	7	0.00
		Shared Voting Power
	8	0.00
	9	Sole Dispositive Power

	0.00
	Shared Dispositive Power
10	0.00
	Aggregate amount beneficially owned by each reporting person
11	0.00
	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
12	☐
	Percent of class represented by amount in Row (11)
13	0 %
	Type of Reporting Person (See Instructions)
14	CO

SCHEDULE 13D

Item 1. Security and Issuer

Title of Class of Securities:

- (a) ORDINARY SHARES of (euro)0.01 par value per share

Name of Issuer:

- (b) DAVION HEALTHCARE PLC

Address of Issuer's Principal Executive Offices:

- (c) Unit A, West Cork Business & Technology Park, Clonakilty, County Cork, IRELAND , P85 FV48.

Item 1 This Amendment No. 1 relates to the Ordinary Shares, nominal value (euros) 0.01 per share, of Davion Healthcare
Comment: plc. The information set forth in Item 1 of the Schedule 13D is incorporated herein by reference and remains unchanged except as otherwise provided herein.

Item 2. Identity and Background

- (a) Jack Harry Kaye Rallinson Corp Rallinson Ltd

The Cube Monahan Road Cork T12 H1XY Ireland 111 NE 1st St Suite 88417 Miami FL 33132 Andrea Kariolou 38 Ayios Athanasios CY 4102 Limassol Cyprus

- (c) This Statement is being filed jointly by Jack Kaye ("Mr. Kaye"), Rallinson Corp ("Rallinson Corp") and Rallinson Ltd ("Rallinson Ltd" and, together with Mr. Kaye and Rallinson Corp, the "Reporting Persons"). Mr. Kaye's business address is The Cube, Monahan Road, Cork, T12 H1XY, Ireland. Mr. Kaye is the Chief Executive Officer and a director of the Issuer. Rallinson Corp is a corporation organized under the laws of Wyoming, United States, whose principal business is investment holding. Rallinson Corp's principal office is located at 111 NE 1st St, Suite 88417, Miami, Fla, 33132, USA. Mr. Kaye is the sole director and sole shareholder of Rallinson Corp and is its ultimate beneficial owner. Rallinson Ltd is a private limited company organized under the laws of Cyprus whose principal business is investment holding. Rallinson Ltd principal office is located at Andrea Kariolou 38, Ayios Athanasios, CY 4102, Limassol, Cyprus. Mr. Kaye is the sole director and sole shareholder of Rallinson Ltd and is its ultimate beneficial owner. As a result of the relationships described above, Mr. Kaye may be deemed to control each of Rallinson Corp and Rallinson Ltd.

- (d) During the last five years, none of the Reporting Persons, and to the best knowledge of the Reporting Persons, none of the directors or executive officers of Rallinson Corp or Rallinson Ltd, has been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanours) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which such person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation of such laws.

- (e) During the last five years, none of the Reporting Persons, and to the best knowledge of the Reporting Persons, none of the directors or executive officers of Rallinson Corp or Rallinson Ltd, has been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanours) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which such person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation of such laws.

- (f) Mr. Kaye is a citizen of the United Kingdom. Rallinson Corp is organized under the laws of Wyoming, USA, and

Rallinson Ltd is organized under the laws of Cyprus.

Item 3. Source and Amount of Funds or Other Consideration

No funds or other consideration were paid or received in connection with the transfers described in this Amendment No. 1. On August 11, 2026, Rallinson Corp transferred 1,245,000 Ordinary Shares to Jack Harry Kaye, and Rallinson Ltd transferred 3,860,530 Ordinary Shares to Jack Harry Kaye. Mr. Kaye was the ultimate beneficial owner of such Ordinary Shares immediately before the transfers and remained the beneficial owner immediately following the transfers. Accordingly, the transfers did not involve the expenditure of funds by Mr. Kaye and did not result in any change in his aggregate beneficial ownership or pecuniary interest in the Ordinary Shares.

Item 4. Purpose of Transaction

On August 11, 2026, Rallinson Corp transferred 1,245,000 Ordinary Shares of the Issuer to Jack Harry Kaye for no consideration, and Rallinson Ltd transferred 3,860,530 Ordinary Shares of the Issuer to Mr. Kaye for no consideration. Mr. Kaye is the sole director, sole shareholder and ultimate beneficial owner of Rallinson Corp and Rallinson Ltd and was the beneficial owner of the Ordinary Shares held through those entities immediately prior to the transfers. The transfers were undertaken solely for the purpose of consolidating Mr. Kaye's holdings of Ordinary Shares into his personal name and converting the manner in which such shares are held from indirect ownership through Rallinson Corp and Rallinson Ltd to direct ownership by Mr. Kaye. No Ordinary Shares were purchased from or sold to any third party in connection with the transfers, no consideration was paid or received, and the transfers did not result in any change in Mr. Kaye's aggregate beneficial ownership or pecuniary interest in the Ordinary Shares. Immediately prior to the transfers, Mr. Kaye beneficially owned an aggregate of 10,268,948 Ordinary Shares, consisting of: (a) 5,163,418 Ordinary Shares held directly by Mr. Kaye; (b) 1,245,000 Ordinary Shares held through Rallinson Corp; and (c) 3,860,530 Ordinary Shares held through Rallinson Ltd. Immediately following completion of the transfers, Mr. Kaye continued to beneficially own the same aggregate 10,268,948 Ordinary Shares, all of which are held directly in his own name. Except as described herein, this Amendment No. 1 does not modify the information previously disclosed under Item 4 of the Schedule 13D.

Item 5. Interest in Securities of the Issuer

As of August 11, 2026, Jack Harry Kaye beneficially owns 10,268,948 Ordinary Shares of the Issuer. Following completion of the transfers described herein, all 10,268,948 Ordinary Shares are held directly by Mr. Kaye. Based upon 25,000,000 Ordinary Shares outstanding, Mr. Kaye beneficially owns approximately 41.08% of the Issuer's outstanding Ordinary Shares. Mr. Kaye has: Sole voting power: 10,268,948 Ordinary Shares Shared voting power: 0 Ordinary Shares Sole dispositive power: 10,268,948 Ordinary Shares Shared dispositive power: 0 Ordinary Shares

(a) Rallinson Corp Prior to the transfer described herein, Rallinson Corp held 1,245,000 Ordinary Shares of the Issuer. On August 11, 2026, Rallinson Corp transferred all 1,245,000 Ordinary Shares held by it to Mr. Kaye for no consideration. Following the transfer, Rallinson Corp beneficially owns 0 Ordinary Shares, representing 0% of the outstanding Ordinary Shares. Rallinson Ltd Prior to the transfer described herein, Rallinson Ltd held 3,860,530 Ordinary Shares of the Issuer. On August 11, 2026, Rallinson Ltd transferred all 3,860,530 Ordinary Shares held by it to Mr. Kaye for no consideration. Following the transfer, Rallinson Ltd beneficially owns 0 Ordinary Shares, representing 0% of the outstanding Ordinary Shares.

As of August 11, 2026, Jack Harry Kaye beneficially owns 10,268,948 Ordinary Shares of the Issuer. Following completion of the transfers described herein, all 10,268,948 Ordinary Shares are held directly by Mr. Kaye. Based upon 25,000,000 Ordinary Shares outstanding, Mr. Kaye beneficially owns approximately 41.08% of the Issuer's outstanding Ordinary Shares. Mr. Kaye has: Sole voting power: 10,268,948 Ordinary Shares Shared voting power: 0 Ordinary Shares Sole dispositive power: 10,268,948 Ordinary Shares Shared dispositive power: 0 Ordinary Shares

(b) Rallinson Corp Prior to the transfer described herein, Rallinson Corp held 1,245,000 Ordinary Shares of the Issuer. On August 11, 2026, Rallinson Corp transferred all 1,245,000 Ordinary Shares held by it to Mr. Kaye for no consideration. Following the transfer, Rallinson Corp beneficially owns 0 Ordinary Shares, representing 0% of the outstanding Ordinary Shares. Rallinson Ltd Prior to the transfer described herein, Rallinson Ltd held 3,860,530 Ordinary Shares of the Issuer. On August 11, 2026, Rallinson Ltd transferred all 3,860,530 Ordinary Shares held by it to Mr. Kaye for no consideration. Following the transfer, Rallinson Ltd beneficially owns 0 Ordinary Shares, representing 0% of the outstanding Ordinary Shares.

On August 11, 2026: Rallinson Corp transferred 1,245,000 Ordinary Shares to Mr. Kaye for no consideration; and Rallinson Ltd transferred 3,860,530 Ordinary Shares to Mr. Kaye for no consideration. The transfers constituted a change in the manner in which securities already beneficially owned by Mr. Kaye were held and did not result in any change in his aggregate beneficial ownership or pecuniary interest in the Ordinary Shares. Except for the foregoing, the Reporting Persons have not effected any transactions in the Ordinary Shares during the past 60 days.

(c) Not applicable.

(d) As a result of the transfers described herein, on August 11, 2026, each of Rallinson Corp and Rallinson Ltd ceased to be the beneficial owner of any Ordinary Shares of the Issuer. Accordingly, following the filing of this Amendment No. 1, Rallinson Corp and Rallinson Ltd will cease to have an ongoing reporting obligation under Section 13(d) with respect to the Ordinary Shares unless either subsequently becomes a beneficial owner subject to such reporting requirements.

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

Except as described in this Amendment No. 1, the information previously disclosed in Item 6 of the Schedule 13D remains unchanged. There was no purchase agreement, sale agreement or other arrangement providing for the payment of consideration in connection with the transfers described herein.

Item 7. Material to be Filed as Exhibits.

The Reporting Persons do not believe that any additional material agreement is required to be filed as an exhibit solely as a result of the transfers described in this Amendment No. 1. To the extent required, the joint filing agreement previously filed with the Schedule 13D is incorporated herein by reference.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

JACK HARRY KAYE

Signature: /s/ Jack Harry Kaye

Name/Title: Jack Kaye, Chief Executive Officer, Davion
Healthcare Plc

Date: 08/11/2026

RALLINSON CORP

Signature: /s/ Jack Kaye

Name/Title: Jack Kaye, beneficial owner of Rallinson Corp

Date: 08/11/2026

RALLINSON LTD

Signature: /s/ Jack Kaye

Name/Title: Jack Kaye, beneficial owner of Rallinson Ltd

Date: 08/11/2026